ABSTRACT
Trade name: Qualaquin (URL Pharma) Indications: Malaria Class: Antimalarial, Antiprotozoal Half-life: 8-14 hours Clinically important, potentially hazardous interactions with: amantadine, amiodarone, amitriptyline, amoxapine, anisindione, anticoagulants, arsenic, artemether / lumefantrine, astemizole, atazanavir, atorvastatin, cimetidine, cisapride, citalopram, class Ia or III antiarrhythmics, clevidipine, CYP3A4 and CYP2D6 substrates, CYP3A4 inducers or inhibitors, darunavir, dasatinib, degarelix, dicumarol, digoxin, disopyramide, dofetilide, dolasetron, droperidol, enalapril, flecainide, fosamprenavir, halofantrine, haloperidol, histamine, indinavir, lapatinib, levofloxacin, mefloquine, metformin, moxifloxacin, nelfinavir, neuromuscular blocking agents, olmesartan, oral typhoid vaccine, pazopanib, pimozide, procainamide, prochlorperazine, quinapril, quinidine, ramipril, rifampin, ritonavir, saquinavir, sotalol, succinylcholine, telavancin, telithromycin, terfenadine, tipranavir, voriconazole, vorinostat, warfarin, ziprasidone Pregnancy category: C Note: Qualaquin (quinine sulfate) is not idicated for the prevention or treatment of nocturnal leg cramps. Contraindicated in patients with prolongation of QT interval, G6PD deficiency, myasthenia gravis, or optic neuritis.
